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a. For	subjects	without	a	previously	document	history	of	glaucoma,	Humphrey	24-2	SITA	Standard	visual	field	testing	confirming	diagnosis	of	glaucoma	must	be	performed	at	least	twice	by	the	time	of	the	Baseline	Visit.	b. For	subjects	who	have	utilized	ocular	hypotensive	medications	for	≥	3	months	prior	to	the	Screening	Visit	but	who	have	visual	field	mean	deviation	scores	≥	0	dB,	nerve	findings	characteristic	of	glaucoma	must	be	documented.	Any	of	the	following	optic	disc	and	nerve	fiber	layer	findings	are	considered	characteristic	of	glaucoma:	i. Cupping	with	increased	vertical	cup-to-disc	ratio	ii. Nerve	fiber	layer	loss	consistent	with	glaucoma	iii. Segmental	loss	of	neuroretinal	rim	(notching	of	the	rim)	iv. Presence	of	a	splinter	disc	hemorrhage	Optical	scanning	lasers	may	be	used	to	document	and	support	the	presence	of	glaucomatous	optic	nerve	changes,	but	may	not	be	considered	as	a	substitute	for	ophthalmoscopy	for	the	purpose	of	establishing	glaucoma	diagnosis.	Acceptable	optical	scanning	laser	diagnostics	include:	
§ Heidelberg	Retina	Tomography	(HRT):	abnormal	nerve	fiber	layer	(NFL)	findings	indicated	by	a	yellow	exclamation	mark	and/or	a	red	x.	
§ Zeiss/Humphrey	Glaucoma	Diagnostic	Unit	(GDx):	abnormal	NFL	findings	with	a	Nerve	Fiber	Index	(NFI)	reading	of	>	31	and/or	<	5%	p-value	indicator	for	NFL.	





Subject	Exclusion	Criteria	(COMPASS	Trial)	Excluded	from	the	study	will	be	individuals	with	the	following	characteristics.	Unless	specified	otherwise,	all	ocular	criteria	refer	to	the	study	eye	only.	1. Inability	to	complete	a	reliable	24-2	SITA	Standard	Humphrey	visual	field	on	the	study	eye	at	screening	(fixation	losses,	false	positive	errors	and	false	negative	errors	should	not	be	greater	than	30%).	2. Use	of	more	than	3	ocular	hypotensive	medications.	(Combination	medications	count	as	2	medications.)	3. Use	of	oral	hypotensive	medication	treatment	for	glaucoma	in	the	fellow	eye.	4. Significant	risk	by	a	washout	of	medication	including	those	subjects	with	advanced	glaucoma	evidenced	by	an	afferent	pupillary	defect,	a	C:	D	ratio	≥	0.9	or	encroachment	of	field	loss	within	the	central	5	degrees	as	indicated	by	≥	2	depressed	points	of	0.5%	probability	on	the	24-2	SITA	Standard	Humphrey	visual	field.	5. Previous	glaucoma	procedure	with	or	without	an	implantable	glaucoma	device	(with	exception	of	laser	treatments	to	the	trabecular	meshwork	such	as	a	Laser	Trabeculoplasty	performed	more	than	three	months	prior	to	study	enrollment.)	6. History	of	elevated	intraocular	pressure	due	to	steroid	response.	7. Proliferative	diabetic	retinopathy.	8. Previous	surgery	for	retinal	detachment.	9. Central	corneal	thickness	>	620	microns.	10. Clinically	significant	corneal	dystrophy.	11. Previous	corneal	surgery.	12. Wet	age-related	macular	degeneration.	13. Clinically	significant	ocular	pathology,	other	than	cataract	and	glaucoma.	14. Diagnosis	of	acute	angle	closure,	traumatic,	congenital,	malignant,	uveitic,	pseudoexfoliative,	pigmentary	or	neovascular	glaucoma.	15. Best	corrected	visual	acuity	worse	than	20/80	in	the	fellow	eye.	
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16. Clinically	significant	ocular	inflammation	or	infection	within	thirty	days	prior	to	screening.	17. Uncontrolled	systemic	disease	that	in	the	opinion	of	the	Investigator	would	put	the	subject's	health	at	risk	and/or	prevent	the	subject	from	completing	all	study	visits.	18. Pregnant	or	nursing	females.	
Subject	Inclusion	Criteria	(Current	Study)	1. Both	male	and	female	subjects	with	no	preference	given	to	either	gender.		2. Must	have	been	previously	enrolled	in	COMPASS	trial	and	returned	to	general		 clinic.		































The COMPASS trial was the pivotal FDA clinical trial that endorsed the approval of the 
CyPass in the United States.13 It was a 2-year randomized trial with over 500 patients involved, 
and represented the largest interventional MIGS trial to date.  Three hundred seventy-four 
patients received the CyPass device.  The study compared the efficacy and safety of patients 
with POAG undergoing CyPass implantation in conjunction with cataract surgery versus those 
undergoing cataract surgery alone.  Our center enrolled 88 patients in the trial, 64 in the 
treatment group and 24 in the control group (Figure 4, Site 05).  The 45 patients in the current 
trial represent a long-term follow up subgroup that had exited the study and returned to general 
clinic.  Our findings demonstrate that the CyPass Micro-Stent has good long-term effectiveness 
in the treatment of mild-moderate POAG when combined with cataract surgery.  A significantly 
higher percentage of eyes in the CyPass group (61%) versus control (17%) maintained an IOP 
of ≤ 18 mmHg without the need for medical therapy, laser trabeculoplasty, or incisional 
surgical intervention (p < 0.05) (Table 2).  No patient had an IOP of lower than 6, and there 
were no incidences of hypotony maculopathy or corneal decompensation.  By comparison, the 
COMPASS trial demonstrated 65% of all microstented subjects maintaining washout IOP of 
between 6 and 18 mmHg inclusive at 24 months in per-protocol (PP) analysis vs. 44% in 
control group.13 In intention-to-treat (ITT) analysis the 24-month proportion of COMPASS 
patients achieving an IOP level of 6 to 18 mmHg were 61% in microstented subjects vs. 44 % 
in control group (P<0.001).13 The results of the current study are nearly equivalent to that of 
microstented subjects in COMPASS, and demonstrate that patients continued to maintain a 
good level of IOP control after a 24-month period with significantly longer follow up in the 
current study, compared with control patients having poorer IOP control, more medication 
usage, and incisional surgical intervention over the same time period of time.  Patients in the 
current study also required less ocular hypotensive medications than control, 0.4 ± 0.7 vs. 0.9 ± 
0.7 respectively (p=0.01) (Figure 5).  Comparatively microstented patients in COMPASS 
required 0.2 ± 0.6 medications vs. 0.6 ± 0.8 in control group.13 Although not statistically 
significant, there was a clear trend when comparing IOP reduction at medicated baseline vs. 
last follow up in the current study, with the microstent group obtaining a reduction of 17.7 ± 
3.3 to 15.0 ± 4.4 (15% reduction) vs. 18.6 ± 4.4 to 17.7 ± 4.8 in control group (5% reduction) 
(p=0.08) (Figure 6).  When evaluating the subset of patients that were classified as “complete 
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success” in the CyPass group (20 of 33 eyes), and comparing washout IOP at baseline to 
postoperative IOP, patients had a reduction in IOP from a mean of 23.75 ± 1.75 mmHg to 
14.30 ± 2.89 (40% reduction) (p<0.001) at an average follow up of 6.27 years.  Preoperatively 
this group went from 1.35 ± 0.93 medications to zero at follow up. 
 One of 33 (3%) eyes underwent secondary incisional surgical intervention (trabecular 
outflow procedure) in the CyPass group versus 3 of 12 eyes (25%) in the control group, with 2 
eyes undergoing a trabecular outflow type procedure and 1 eye requiring a trabeculectomy.  
There was no progression in visual fields in either group (p=0.93).  This finding is somewhat 
surprising given that patients in the control group had a trend toward higher IOP levels, 
however the control group still maintained a mean IOP of under 18 mmHg (17.7 ± 4.8), albeit 
at the expense of higher medication usage and more surgical intervention needed to achieve 
this goal.  It is possible that changes in visual field loss between groups would manifest over a 
longer follow up period.  Furthermore, there is often a discrepancy between functional and 
structural changes in glaucoma, and many patients may show progressive structural changes in 
the absence of changes on automated visual field testing21.  As long-term nerve fiber layer data 
was not collected, we are unable to be certain if there were changes in this parameter. 
           The CyPass Microstent compares favorably to other MIGS procedures/devices, however 
caution must be exercised when comparing trial results secondary to different methodologies 
used as well as different inclusion/exclusion criteria.  The iStent trabecular micro-bypass 
device is implanted through the trabecular meshwork to target Schlemm’s canal and enhance 
trabecular outflow.22  At the 24-month time point 61% of patients in the stent group achieved 
an unmedicated IOP of ≤	21 mmHg, compared with 61% in the current trial meeting the more 
stringent criterion of ≤	18	mmHg.23		Furthermore,	the	difference	in	the	anti-glaucoma	medication	usage	between	the	stent	group	and	control	group	had	dissipated	by	the	24	month	mark,	while	it	remained	clinically	significant	in	the	current	trial	at	a	mean	of	over	6	years.		The HORIZON trial was a randomized clinical trial comparing another trabecular 
device, the Hydrus Microstent, (Ivantis Inc, Irvine, CA), in combination with 
phacoemulsification.  At 24 months the microstent group demonstrated a 7.6 reduction in mean 
IOP versus baseline versus 9.5 mmHg at over 5 years in the current trial when considering 
unmedicated patients, demonstrating approximately a 2-point benefit in IOP reduction for the 
CyPass Micro-Stent. Although the XEN gel stent may be considered a MIGS procedure, it is 
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indicated for more severe refractory glaucoma in which prior surgery or medications have 
failed, rather than mild-moderate glaucoma.24  Made of a porcine gelatin material, it is 
implanted ab interno and creates a conduit from the anterior chamber into the subconjunctival 
space to allow for aqueous outflow.24  Studies of the current Xen model have demonstrated an 
IOP lowering effect from 29% to 45% with anywhere from 39% to 90% of patients medication 
free postoperatively.25  This is in line with the current study in which there was a 39% drop in 
IOP along with 61% of patients being medication free postoperatively.  Additionally, there is no 
chance of conjunctival fibrosis following implantation of the CyPass Micro-Stent as there is 
with the Xen implant, leaving room for future filtering surgery if needed.  
  Glaucoma surgery must not only be efficacious but demonstrate adequate safety over a 
period of time.  This is especially true for MIGS procedures, as they are utilized earlier in the 
disease process.  One of many safety parameters measured during FDA clinical trials involving 
MIGS procedures is endothelial cell loss (ECL). At the time of this writing (early September 
2018), Alcon globally withdrew the CyPass Micro-Stent based on concerns of progressive ECL 
shown in the COMPASS-XT trial.  Performed at the request of the FDA, the COMPASS-XT 
trial was a 3-year extension of the 2-year COMPASS trial and included 282 of the 505 patients 
enrolled in the COMPASS trial, with 253 patients completing the 60-month visit.  At the end of 
the 24-month COMPASS trial, the treatment and control group demonstrated similar mean and 
percentage of eyes with > 30% ECL.  However, by the 60-month follow up visit, the CyPass 
group had shown a significantly higher mean and percentage of eyes with ECL (Figures 7 and 
8, data available at (www.alcon.com/cypass).  The only variable found to be correlated with 
progressive ECL was device positioning (Figure 9).  Based on this data, it seems as though the 
ideal position of the device is with no retention rings visible, with the anterior position of the 
device at or below the trabecular meshwork.  When positioned in this manner, an ECL of 
1.39% per year occurred, which is more in line with what is expected for patients with 
glaucoma, although this is still higher than control group loss of 0.36% per year.26  During the 
clinical trial, surgeons were instructed to implant the device with an optimal position of 1 ring 
visible, which is reflected in FDA “directions for use” (DFU).  Only 1 patient developed mild 
corneal edema at 51 months during COMPASS-XT, and this was successfully resolved with 
device trimming a subsequent resolution of edema.  The CyPass Micro-Stent compares 
favorably with ECL after traditional glaucoma surgery, with tube shunts demonstrating up to 
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24.6% reduction in mean ECL at 4 years, and trabeculectomy up to 28% at 1 year.27,28  
Compared with other MIGS procedures, the CyPass has shown greater ECL although the 
follow period in other trials has not been as long.  In example, the Hydrus Microstent exhibited 
14% mean ECL at 2 years versus 18.4 % for CyPass at 5 years.  Our group is currently working 
on a trial to reexamine all original COMPASS patients from our site and revaluate stent 






 In conclusion, the CyPass Micro-Stent combined with cataract surgery demonstrates 
good long-term efficacy over cataract surgery alone in patients with mild-moderate POAG.  



























Parameter	 CyPass	 Control	 P-Value	N	(eyes)	 33	 12	 −	Female	Count	(Percent)	 19	(57.6)	 14	(42.4)	 −	Right	Eyes	Count	(Percent)	 16	(48.5)	 8	(66.7)	 −	Mean	Age	±	SD	 66.8	±	7.3	 65.9	±	5.5	 0.53	Mean	Pre	VF	±	SD	 -3.1	±	2.3	 -3.3	±	2.5	 0.73	Mean	Post	VF	±	SD	 -3.7	±	2.7	 -3.6	±	2.2	 0.93	Mean	Pre	IOP	WO	±	SD	 24.4	±	2.6	 24.1	±	2.4	 0.61	Mean	Pre	IOP	±	SD	 17.7	±	3.3	 18.6	±	4.4	 0.76	Mean	Post	IOP	±	SD	 15.0	±	4.4	 17.7	±	4.8	 0.08	Mean	Pre	Med	±	SD	 1.5	±	1.0	 1.3	±	1.0	 0.58	Mean	Post	Med	±	SD	 0.4	±	0.7	 0.9	±	0.7	 0.01*	Mean	Days	PO	±	SD	 2298.1	±	433	 2419.3	±	469.2	 0.43	Pre	VF=preoperative	Humphrey	mean	deviation;	Post	VF=postoperative	Humphrey	mean	deviation;	Pre	IOP	WO=preoperative	washout	IOP	found	in	COMPASS	trial;	Pre	IOP=	preoperative	intraocular	pressure	at	COMPASS	screening;	Post	IOP=	postoperative	intraocular	pressure	at	last	clinic	exam;	Pre	Med=	preoperative	glaucoma	medication	usage	at	COMPASS	screening;	Post	Med=	postoperative	glaucoma	medication	usage	at	last	clinic	exam;	Days	PO=	days	since	surgery;*P<0.05					 		
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Table 2. Success, Qualified 








Complete Success  20 (60.6) 2 (16.7) 0.008 
Qualified Success 9 (27.3) 5 (41.7)  
Failure 4 (24.2) 5 (41.7)  				
Table	3.	Reasons	for	
“Qualified	Success”	or	
“Failure”.	 Qualified	 Failure	SLT	 Med	 Mult	 IOP	 Med	 Sx	 Mult	
CyPass	 2	 5	 2	 1	 1	 0	 2	
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